Could Zelsuvmi Be The Answer To Skin Cancer?
Table of Contents
What Is Zelsuvmi Used For?
ZELSUVMI™ (berdazimer) is a first-in-class topical medication that was approved by the U.S. Food and Drug Administration on January 5, 2024, making it the first new drug for the treatment of molluscum contagiosum.
Zelsuvmi is the first FDA-approved prescription medication specifically designed to treat molluscum contagiosum (MC) in adults and children aged one year and older.
This topical gel offers a non-invasive, at-home treatment option, eliminating the need for in-office procedures like cryotherapy or curettage.
About Molluscum Contagiosum
Molluscum contagiosum (MC) is a skin infection caused by the molluscum contagiosum virus (MCV), which mainly infects children, but can also be seen in adults, especially those with weakened immune systems.
They appear as small, raised, flesh-colored bumps on the skin, usually on the genital area, abdomen, arms, and legs.
MCV is spread by direct skin-to-skin contact, as well as through contaminated objects such as towels or clothing.
Although MC is usually benign and self-limiting, it can cause discomfort, itching and cosmetic problems.
Mechanism Of Action
Zelsuvmi, a topical gel containing 10.3% berdazimer, is a breakthrough drug for the treatment of MC, offering a promising approach to the treatment of this common viral skin infection.
It has a unique mechanism of action that targets MCV and its replication cycle. Its active ingredient, Berdazimer, acts as a potent inhibitor of viral replication by disrupting key molecular pathways involved in viral transmission.
Specifically, Berdazimer interferes with the synthesis and assembly of viral DNA, ultimately inhibiting viral replication and transmission.
In addition, berdazimer has immunomodulatory properties that enhance the body’s natural defense against MCV infection.
This dual mechanism of action not only inhibits viral proliferation, but also promotes regression of existing lesions, providing patients with a comprehensive approach to MCV treatment.
Clinical Trials
The results of the Phase III clinical trial (B-SIMPLE4) of Zelsuvmi gel are significant for patients with molluscum contagiosum.
In the trial, patients with a mean number of approximately 20 starting lesions were treated with 10.3% Zelsuvmi gel once daily for 12 weeks.
Results showed that 32.4% (n = 444) of Zelsuvmi-treated patients had complete resolution of their lesions, compared to 19.7% (n = 447) of placebo-treated patients.
This means that for every 100 patients treated with Berdazimer, 32 lesions disappeared completely, compared to 20 lesions in patients treated with placebo.
The odds ratio (OR) was 2.0, with a 95% confidence interval (CI) of 1.5 to 2.8 and a p-value of <0.001, indicating a statistically significant difference in treatment effect between the two groups
Differences With Existing Therapies
Zelsuvmi offers several advantages over treatments such as cryotherapy or topical medications.
Its targeted mechanism of action directly targets viral replication, potentially accelerating lesion regression and reducing transmission.
Zelsuvmi’s topical formulation can also be conveniently administered at home, improving patient compliance and treatment adherence.
In addition, Zelsuvmi has a favorable safety profile and low risk of systemic side effects, differentiating it from many existing therapies and making it a preferred choice for patients and healthcare providers.
Dosage And Administration
Fill Test Tube A and Test Tube B with equal amounts (0.5 mL) of gel from the dosing guide.
Immediately tighten the lids of Test Tube A and Test Tube B. Mix together on the Dosing Guide.
Immediately apply ZELSUVMI as a thin, uniform layer. Apply it to each MC lesion once daily for up to 12 weeks.
Wash your hands after applying Berdazimer unless your hands are being treated.
Allow ZELSUVMI to dry 10 minutes after application.
Avoid applying ZELSUVMI to uninfected skin and avoid transferring applied ZELSUVMI to other areas, including the eyes.
Avoid swimming, bathing, or washing your face for 1 hour after applying ZELSUVMI.
Berdazimer is for topical use only and should not be used in the eye, mouth, or vagina.
Adverse Reactions
The most commonly reported adverse reactions (≥1%) are application site reactions including
🔴pain (such as burning or stinging sensations, 18.7%),
🔴erythema (11.7%),
🔴pruritus (5.7%),
🔴exfoliation (5.0%),
🔴dermatitis (4.9%),
🔴swelling (3.5%),
🔴erosion (1.6%),
🔴discoloration (1.5%),
🔴vesicles (1.5%),
🔴irritation (1.2%),
🔴infection (1.1%).
Final Thoughts
Zelsuvmi is gaining traction for all the right reasons. Whether you’re looking for a new tool to enhance your workflow or simply curious about what’s next in your industry, Berdazimer deserves your attention.
About DengYueMed – HK Drug Wholesale Distributor
As a legally compliant drug import and export company, DengYueMed is certified by the pharmacy & poisons board of Hong Kong — you can verify our qualification on their official website.
Our efforts to improve the affordability of Zelsuvmi medicine aim to ensure that more patients can benefit from this important medication.
HK DengYue provides detailed medicine information, transparent pricing, and responsive support to ensure a smooth and reliable buying experience.
Feel free to reach out anytime to discuss your needs or ask questions about the medicine.
We welcome you to contact us for a consultation.
